Novel Immune Therapies for Renal Cell Carcinoma: Looking Beyond the Programmed Cell Death Protein 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 Axes.
Adoptive cell therapies
Cancer vaccines
Cytokines
Immune checkpoints
Immuno-metabolic pathways
Myeloid cell targets
Renal cell carcinoma
Journal
Hematology/oncology clinics of North America
ISSN: 1558-1977
Titre abrégé: Hematol Oncol Clin North Am
Pays: United States
ID NLM: 8709473
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
medline:
18
9
2023
pubmed:
1
7
2023
entrez:
30
6
2023
Statut:
ppublish
Résumé
Immunotherapy has revolutionized treatment for patients with advanced and metastatic renal cell carcinoma. Nevertheless, many patients do not benefit or eventually relapse, highlighting the need for novel immune targets to overcome primary and acquired resistance. This review discusses 2 strategies currently being investigated: disabling inhibitory stimuli that maintain immunosuppression ("brakes") and priming the immune system to target tumoral cells ("gas pedals"). We explore each class of novel immunotherapy, including the rationale behind it, supporting preclinical and clinical evidence, and limitations.
Identifiants
pubmed: 37391289
pii: S0889-8588(23)00078-3
doi: 10.1016/j.hoc.2023.05.023
pii:
doi:
Substances chimiques
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Review
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1027-1040Subventions
Organisme : NCI NIH HHS
ID : P30 CA016359
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosures Conflicts of Interest: E. Saad, R.M. Saliby, C. Labaki: none. W. Xu reports advisory board fees from Exelixis and Jazz Pharmaceuticals, and continuing medical education honoraria from MedNet, Harborside Press, MJH Healthcare Holdings, and Academy for Continued Healthcare Learning. S.R. Viswanathan reports consulting for Jnana Therapeutics, MPM Capital, and Vida Ventures within the last 3 years and research support from Bayer, Germany. Spouse is an employee of and holds equity in Kojin Therapeutics. D.A. Braun reports honoraria from LM Education/Exchange Services, advisory board fees from Exelixis and AVEO, personal fees from Schlesinger Associates, Cancer Expert Now, Adnovate Strategies, MDedge, CancerNetwork, Catenion, OncLive, Cello Health BioConsulting, PWW Consulting, Haymarket Medical Network, Aptitude Health, ASCO Post/Harborside, Targeted Oncology, AbbVie, and research support from Exelixis and AstraZeneca, outside of the submitted work. Z. Bakouny reports research support from Genentech, United States/imCORE and Bristol Myers Squibb, United States, and honoraria from UpToDate.